Galectin Therapeutics Inc (GALT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $304.57M
Last updated: Nov 17, 2026 at 4:18 PM ET
Galectin Therapeutics Inc (GALT) Stock Chart
Galectin Therapeutics (GALT) has a latest price of $2.91 on Nov 17, 2026, 59.2% below its 52-week high of $7.13. Its price fell 47.2% over the past 12 months. The month-end price rose 361.1% over the 10 years through Oct 2026, a compound annual rate of 16.5%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $6.47 in Aug 2018 and its lowest $0.72 in Oct 2016, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart GALT with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for GALT.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 20.7%, and over 6 months it rose 39.9%. The month-end price rose 62.7% over the 3 years through Oct 2026, a compound annual rate of 17.6%.
| Period | Change |
|---|---|
| 1 month | -16.7% |
| 3 months | -20.7% |
| 6 months | +39.9% |
| 12 months | -47.2% |
| 12 months, with dividends | -47.2% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +62.7% | +17.6% |
| 5 years | +4.7% | +0.9% |
| 10 years | +361.1% | +16.5% |
Price by Year
Its best calendar year was 2017, when the price rose 240.9%, and its weakest was 2022, when it fell 45.4%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $3.32 | -20.2% |
| 2025 | $4.16 | +222.5% |
| 2024 | $1.29 | -22.3% |
| 2023 | $1.66 | +46.9% |
| 2022 | $1.13 | -45.4% |
| 2021 | $2.07 | -7.6% |
| 2020 | $2.24 | -21.7% |
| 2019 | $2.86 | -16.6% |
| 2018 | $3.43 | +2.7% |
| 2017 | $3.34 | +240.9% |
Trading Range
The price is 19.0% below its 50-day average of $3.59 and 9.5% below its 200-day average of $3.21.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $2.91 | |
| 52-week high | $7.13 | -59.2% |
| 52-week low | $2.03 | +43.3% |
| 50-day average | $3.59 | -19.0% |
| 200-day average | $3.21 | -9.5% |
Price Risk
Over 3 years, its largest fall from a peak was 80.0%.
| Measure | Value |
|---|---|
| 1-year beta | 1.11 |
| Largest fall, 1 year | -68.0% |
| Largest fall, 3 years | -80.0% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About GALT
What is GALT's 1-year price change?
Galectin Therapeutics's price fell 47.2% over the past 12 months. With dividends included, the 12-month total return was -47.2%.
What is GALT's 5-year price change?
Galectin Therapeutics's month-end price rose 4.7% over the 5 years through Oct 2026, a compound annual rate of 0.9%. These figures leave out dividends.
What is GALT's 52-week high and low?
Galectin Therapeutics's 52-week high is $7.13 and its 52-week low is $2.03. Its latest price of $2.91 on Nov 17, 2026 is 59.2% below the high.
What is GALT's beta?
Galectin Therapeutics's 1-year beta against the S&P 500 is 1.11, so its price has moved about in line with the market over the past year. Its largest fall from a peak over the past year was 68.0%.
Is the GALT chart free?
Yes. Advanced Charting for GALT is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
GALT pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors